Henry I. Miller


Henry I. Miller, MS, MD, was the Robert Wesson Fellow in Scientific Philosophy and Public Policy at the Hoover Institution. His research focused on public policy toward science and technology, encompassing a number of areas, including pharmaceutical development, genetic engineering in agriculture, models for regulatory reform, and the emergence of new viral diseases.

Miller served for fifteen years at the US Food and Drug Administration (FDA) in a number of posts. He was the medical reviewer for the first genetically engineered drugs to be evaluated by the FDA and thus instrumental in the rapid licensing of human insulin and human growth hormone. Thereafter, he was a special assistant to the FDA commissioner and the founding director of the FDA's Office of Biotechnology. During his government service, Miller participated frequently on various expert and policy panels as a representative of the FDA or the US government. As a government official, Miller received numerous awards and citations.

During his time at the Hoover Institution, Miller has become well known not only for his contributions to scholarly journals but also for his articles and books that make science, medicine, and technology accessible. His work has been widely published in many languages. Monographs include Policy Controversy in Biotechnology: An Insider's View; To America's Health: A Model for Reform of the Food and Drug Administration; and The Frankenfood Myth: How Protest and Politics Threaten the Biotech Revolution. Barron's selected The Frankenfood Myth as one of the 25 Best Books of 2004. In addition, Miller has published extensively in a wide spectrum of scholarly journals and popular publications worldwide, including The Lancet, Journal of the American Medical Association, Science, the Nature family of journals, Chronicle of Higher Education, Forbes, National Review, Wall Street Journal, New York Times, the Guardian, Defining Ideas, and the Financial Times. He was a regulator contributor to Forbes.com and frequently appeared on the nationally syndicated radio programs of John Batchelor and Lars Larson.

Miller was selected by the editors of Nature Biotechnology as one of the people who had made the "most significant contributions" to biotechnology during the previous decade. He serves on numerous editorial boards.

Filter By:



Recent Commentary

Down on the Biopharm

by Henry I. Miller, David Longtinvia Policy Review
Monday, December 1, 2003

Missing out on the latest benefits of pharmacology

this is an image

While the Government Blunders, West Nile Virus Thrives

by Henry I. Millervia Hoover Digest
Thursday, October 30, 2003

How misguided bureaucrats and environmentalists let a mosquito-borne disease spread. By Henry I. Miller.

Biotech and Baby Food

by Henry I. Miller, Gregory Conkovia Policy Review
Sunday, June 1, 2003

Advancing a political agenda through parental anxiety

Analysis and Commentary

Vaccine Development a Casualty of Flawed Public Policy

by Henry I. Millervia Hoover Daily Report
Monday, May 5, 2003

Vaccines traditionally offer low return on investment but high exposure to legal liability.

A Deadly Food Fight

by Gregory Conko, Henry I. Millervia Hoover Digest
Wednesday, April 30, 2003

Real-life casualties in the biotech wars. By Hoover fellow Henry I. Miller and Gregory Conko.

Analysis and Commentary

Designer Genes: Will They Wash?

by Henry I. Millervia Hoover Daily Report
Monday, March 31, 2003

Innovations such as gene therapy, even when used for enhancement, should be treated similarly to other analogous medical and quasi-medical interventions.

The Academy Takes a Dive

by Henry I. Millervia Hoover Digest
Thursday, January 30, 2003

Has the National Academy of Sciences—long seen as a reliable, independent, and incorruptible source of advice on scientific, technological, and medical issues—been providing the federal government with flawed and politically motivated advice? By Hoover fellow Henry I. Miller.

Analysis and Commentary

A Label We Don't Need

by Henry I. Millervia Hoover Daily Report
Monday, November 18, 2002

Product labeling that conveys essential information is important, but compulsory labeling of gene-spliced foods is a bad idea for several reasons.

How Government Stunted an Industry

by Henry I. Millervia Hoover Digest
Wednesday, October 30, 2002

As it turns 20, how healthy is the biopharmaceutical industry? That depends on how you define “healthy.” By Hoover fellow Henry I. Miller.

The Biggest Pest

by Henry I. Millervia Hoover Digest
Tuesday, July 30, 2002

Gene-spliced crops not only increase yields, reduce the need for agricultural chemicals, and make better use of existing farmland but also are a potential boon to public health. Now if someone would just explain this to the EPA. By Hoover fellow Henry I. Miller.